Retatrutide helps patients lose 30% body weight in trials: Study

Eli Lilly's next-gen obesity drug retatrutide showed patients losing up to 30% body weight over 104 weeks in a late-stage trial, a study showed. The study, involving 2,339 participants across 11 countries, also found the drug reduced knee pain by 62%, sleep apnea events by 57%, and helped over 90% of prediabetic participants recover.